Attenuated Postprandial GLP-1 Response in Parkinson’s Disease

The incretin hormone glucagon-like peptide 1 (GLP-1) has neuroprotective effects in animal models of Parkinson’s disease (PD), and GLP-1 receptor agonists are associated with clinical improvements in human PD patients. GLP-1 is produced and secreted by intestinal L-cells in response to consumption o...

Descripción completa

Detalles Bibliográficos
Autores principales: Manfready, Richard A., Engen, Phillip A., Verhagen Metman, Leo, Sanzo, Gabriella, Goetz, Christopher G., Hall, Deborah A., Forsyth, Christopher B., Raeisi, Shohreh, Voigt, Robin M., Keshavarzian, Ali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Neuroscience
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8283566/
https://www.ncbi.nlm.nih.gov/pubmed/34276285
http://dx.doi.org/10.3389/fnins.2021.660942

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8283566/
https://www.ncbi.nlm.nih.gov/pubmed/34276285
http://dx.doi.org/10.3389/fnins.2021.660942

Ejemplares similares